To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Completed · Phase 2

Conditions studied: Epilepsy, Partial

In brief

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Key facts

Study ID

NCT00141414

Run by

Pfizer

People needed

82

Starts

1997-11-01

Expected to finish

2005-10-01

Last updated by the study team

2007-01-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have met the inclusion criteria for preceding double-blind study.
• Have received double-blind study medication and wish to receive open-label pregabalin.

You may not qualify if…

• Pregnant or considering becoming pregnant.
• Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Where it is running

• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Stanford, California, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Plantation, Florida, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Saint Paul, Minnesota, United States
• Pfizer Investigational Site — Chesterfield, Missouri, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — The Bronx, New York, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States
• Pfizer Investigational Site — Columbus, Ohio, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States
• Pfizer Investigational Site — Bonn, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.